Compared to the EGFR gene, the EGFRvIII variant has missing L1 and CR1 domains due to the deletion of exons 2-7. This truncation results in the inability of the receptor to bind to any ligand thus becoming an important driver in tumor progression and a marker of poor prognosis\cite{Gan2013}.    The EGFR receptor protein has different domains that have different key roles in signaling  \cite{Ferguson2008}. As a result, mutations in the gene expressing them also manifest uniquely in different cancers. For example, mutations in the tyrosine kinase domain are unique to lung cancers \cite{Purba2017}\cite{Lee2010}  while brain tumors show mutations in the autoregulatory domains and the ectodomains of the same gene \cite{Wong1987}\cite{Binder2018}.